Table 1.
CLDN phenotypes † | P‐value* | MUC phenotypes † | P‐values* | |||||
---|---|---|---|---|---|---|---|---|
G‐CLDN n (%) | I‐CLDN n (%) | U‐CLDN n (%) | G‐MUC n (%) | I‐MUC n (%) | U‐MUC n (%) | |||
Total | 28 (30) | 41 (44) | 25 (26) | 22 (23) | 47 (50) | 25 (27) | ||
Sex | ||||||||
Male | 19 (20) | 30 (32) | 19 (20) | 0.793 | 16 (17) | 34 (35) | 18 (19) | 0.998 |
Female | 9 (10) | 11 (12) | 6 (6) | 6 (7) | 13 (14) | 7 (8) | ||
Age (years) | ||||||||
≥68 | 15 (16) | 13 (14) | 10 (10) | 0.191 | 10 (11) | 15 (16) | 12 (13) | 0.330 |
<68 | 13 (14) | 28 (30) | 15 (16) | 12 (13) | 32 (33) | 13 (14) | ||
Size (mm) | ||||||||
≥65 | 19 (20) | 31 (34) | 10 (11) | 0.010* | 14 (15) | 32 (33) | 15 (16) | 0.783 |
<65 | 8 (8) | 10 (11) | 15 (16) | 8 (9) | 15 (16) | 10 (11) | ||
Location ‡ | ||||||||
Upper | 7 (8) | 12 (12) | 3 (3) | 0.541 | 5 (5) | 13 (14) | 4 (4) | 0.784 |
Middle | 11 (12) | 18 (19) | 13 (14) | 10 (11) | 21 (21) | 11 (12) | ||
Lower | 10 (10) | 11 (12) | 9 (10) | 7 (8) | 13 (14) | 10 (11) | ||
Histological type ‡ | ||||||||
W | 10 (10) | 19 (20) | 15 (16) | 0.332 | 8 (9) | 22 (23) | 14 (15) | 0.337 |
P | 18 (19) | 22 (25) | 10 (10) | 15 (16) | 25 (25) | 11 (12) | ||
Depth of invasion ‡ | ||||||||
m + sm | 13 (14) | 8 (10) | 2 (2) | 0.003* | 8 (9) | 10 (11) | 4 (4) | 0.229 |
mp + ss | 15 (16) | 33 (35) | 23 (23) | 14 (15) | 37 (38) | 21 (22) | ||
Vessel infiltration | ||||||||
Lymphatic vessels | ||||||||
Negative | 7 (8) | 7 (8) | 1 (1) | 0.110 | 2 (2) | 9 (10) | 3 (3) | 0.645 |
Positive | 21 (22) | 34 (36) | 24 (25) | 20 (21) | 47 (48) | 25 (26) | ||
Venous vessels | ||||||||
Negative | 13 (14) | 11 (11) | 4 (4) | 0.046* | 8 (9) | 13 (14) | 6 (7) | 0.629 |
Positive | 15 (17) | 30 (32) | 21 (22) | 14 (15) | 34 (35) | 19 (20) | ||
Lymph node metastases | ||||||||
Negative | 11 (12) | 5 (4) | 2 (2) | 0.028* | 6 (7) | 7 (8) | 4 (4) | 0.438 |
Positive | 17 (18) | 36 (40) | 23 (23) | 16 (17) | 40 (42) | 21 (22) | ||
Clinicopathological stage ‡ | ||||||||
I + II | 14 (15) | 13 (14) | 5 (5) | 0.065 | 10 (11) | 16 (17) | 6 (7) | 0.359 |
III + IV | 14 (15) | 28 (30) | 20 (21) | 13 (14) | 30 (32) | 19 (20) |
Statistical analyses were carried out using the χ2‐test. P‐values less than 0.05 were considered to be statistically significant.
† The classification of gastric cancers (GC) with claudin and mucin phenotypes was carried out as described in the text.
Location, histological type, depth of invasion and clinicopathological stage were determined according to the Japanese Classification of Gastric Carcinoma 2nd edn.( 23 ) G‐CLDN, gastric claudin; G‐MUC, gastric mucin; I‐CLDN, intestinal claudin; I‐MUC, intestinal mucin; m, mucosa; mp, muscularis propria; P, poorly differentiated adenocarcinomas including signet‐ring cell carcinomas and mucinous adenocarcinomas; sm, submucosa; ss, subserosa; U‐CLDN, unclassified claudin; U‐MUC, unclassified mucin; W, well‐differentiated adenocarcinomas including papillary adenocarcinomas and tubular adenocarcinomas.